Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 12/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.38 |
| ▸ | UBE2M | P61081 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25880723 | 0.78 | KCNH2 (0.46) | KCNH2OPRK1OPRM1CHRM2CHRM3 | |
| SCHEMBL30833233 | 0.68 | KCNH2 (0.56) | KCNH2OPRK1OPRM1OPRD1 | |
| SCHEMBL22165423 | 0.66 | MEN1 (0.39) | KCNH2OPRK1OPRM1DRD2DRD4 | |
| SCHEMBL521041 | 0.64 | DRD2 (0.36) | KCNH2OPRK1DRD2DRD4SLC6A2 | |
| SCHEMBL30833216 | 0.63 | KCNH2 (0.58) | KCNH2OPRK1OPRM1OPRD1 | |
| SCHEMBL14636209 | 0.62 | CHRM2 (0.46) | KCNH2OPRK1UBE2MDCUN1D1OPRM1 | |
| SCHEMBL5264387 | 0.61 | KCNH2 (0.55) | KCNH2OPRK1OPRM1DRD2DRD4 | |
| SCHEMBL20483452 | 0.60 | CHRM2 (0.64) | KCNH2OPRK1OPRM1DRD2DRD4 | |
| SCHEMBL4591949 | 0.60 | PKM (0.42) | — | |
| SCHEMBL14637727 | 0.60 | CHRM2 (0.42) | KCNH2OPRK1UBE2MDCUN1D1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | RBM17, SF3B1, SF3B5 | KCNH2 4599/4885OPRK1 3864/4885UBE2M 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.